✨ Free AI Report
Fagron NV: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Fagron NV
Company Research

Fagron NV: Business Overview, Financials & Competitive Analysis

Fagron NV scores 7/10 on the AskCyborg Cyborg Score (Strong). Fagron is well-positioned in the personalized medicine market with a scalable platform and disciplined acquisition strategy driving consistent growth across multiple geographies. Fagron demonstrates solid fundamentals with ~$1B revenue, strong market position in pharmaceutical compounding, and global distribution across 60+ countries. Recent acquisitions (Purifarma) and facility expansions show execution on.

What is Fagron NV's industry? Fagron NV (fagron.com) operates in Pharmaceutical Compounding & Healthcare Manufacturing. AskCyborg classifies Fagron NV under Pharmaceutical Compounding & Healthcare Manufacturing in its company registry.

Fagron is a pharmaceutical compounding company operating in Belgium that acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company focuses on optimizing an...

7/ 10Strong

Cyborg Score thesis

Fagron is well-positioned in the personalized medicine market with a scalable platform and disciplined acquisition strategy...

Read the full analyst-debate transcript →
Industry Pharmaceutical Compounding & Healthcare Manufacturing
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Fagron NV Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Fagron NV

AskCyborg analysts argue the bull and bear cases for Fagron NV across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Fagron NV OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Fagron NV Overview

Pro stress-test →

Fagron is a pharmaceutical compounding company operating in Belgium that acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company focuses on optimizing and innovating pharmaceutical compounding to widen the therapeutic scope of prescribers worldwide.

Strategic Profile

Pro stress-test →

Fagron is currently leading in pharmaceutical compounding and is active in 35 countries, with products and innovations sold to over 200,000 customers in over 60 countries around the world. The company intends to achieve growth by growing organically as well as by making selective acquisitions that complement and expand the existing strengths.

Competitive Landscape

Pro stress-test →

Competitors include Medisca (Pharmaceuticals), Farmalabor, Pfizer Manufacturing Austria, Ace Pharmaceuticals, and Nephron Pharmaceuticals. Fagron's differentiation lies in its global network of compounding facilities, diversified product portfolio, and focus on personalized pharmaceutical solutions.

Industry Context

Fagron NV operates in Pharmaceutical Compounding & Healthcare Manufacturing.

Key facts

Founded: 1990 · Headquarters: Rotterdam, Netherlands (operational) / Nazareth, Belgium (registered) · Employees: 3,989 · Revenue: $943M-998M · Market cap: $1.9B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Fagron NV.

  • North America is majority revenue driver with strong Compounding Services and Brands & Essentials segments showing operational excellence
  • Recently signed three acquisitions including Purifarma in Brazil to strengthen regional presence and drive procurement synergies
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Confirmed full-year revenue guidance of €930-950M with improved profitability
  • November 2025Announced three acquisitions including Purifarma in Brazil to expand regional presence
  • +1 moreTrack every material event for Fagron NV as it happens. Explore monitoring →
Get alerted when Fagron NV has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compounding ServicesPharmaceutical compounding and custom formulation services→Pharmaceutical ManufacturingPharmaceutical manufacturing and compounding solutions→Manufacturing ServicesLarge-scale pharmaceutical manufacturing and distribution→

Compare Fagron NV with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Fagron NV operates in Pharmaceutical Compounding & Healthcare Manufacturing. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Compounding & Healthcare Manufacturing research →
NEW · MCP server

Ask your AI assistant about Fagron NV

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Fagron NV and its top competitor on Cyborg Score”
“What did Fagron NV do this quarter?”
“Is Fagron NV a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Fagron NV do?+
Fagron is a pharmaceutical compounding company operating in Belgium that acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company focuses on optimizing an...
What is Fagron NV's Cyborg Score?+
Fagron NV has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Fagron NV's main competitors?+
Named competitors include Compounding Services, Pharmaceutical Manufacturing, Manufacturing Services. The full competitive landscape is in the AskCyborg report.
How can I get the full Fagron NV research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Fagron NV research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Fagron NV over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.